Vanda Strikes Out at the Supreme Court
April 22, 2024, 3:57 PM
Two weeks ago we discussed Vanda Pharmaceuticals’ ambitious cert petition asking the Supreme Court to discontinue the “reasonable expectation of success” standard for patent obviousness that for decades has been a mainstay of patent law.
Vanda argued that the Court should instead adopt a “predictable results” standard, which would have made patents more difficult to challenge and thereby significantly impacted the pharma and biologics industries. Unsurprisingly, the Court today denied Vanda’s petition, leaving the obviousness standard unchanged.

To subscribe to our publications, click here.
Tags
News & Insights
News & Insights
Seven Axinn Attorneys Named to 2025 Capital Pro Bono Honor Roll
Pro Bono
Antitrust
Axinn Advises Thermo Fisher Scientific on $1.075 Billion Sale of its Microbiology Business to Astorg
Deals & Cases
Antitrust
Axinn Appoints Rachael Philbin as Chief Innovation Officer
News
Teva v. Lilly -- Clarifies Written Description of Method Claims Involving A Genus
Axinn Viewpoints
Intellectual Property
What’s Up? Competition Enforcement Updates From Italy and Portugal
Podcast
Antitrust
ACI 22nd Annual Paragraph IV Conference
Speaking Engagement
Intellectual Property
Informa 35th Annual Advanced EU London Conference
Speaking Engagement
Antitrust
Antitrust Fault Lines: Will Licensing Negotiation Groups Reshape SEP Licensing?
Byline Articles
Antitrust
AHLA Health Care Transactions Program 2026
Sponsorship
Antitrust
Kenina Lee Selected as a Member of Law360’s 2026 Competition Editorial Advisory Board
Awards & Recognitions
Antitrust

